4-(1-ethylpropyl)benzoic acid | 860698-63-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-(1-ethylpropyl)benzoic acid
• 英文别名: 4-(1-ethyl-propyl)-benzoic acid；4-(1-Aethyl-propyl)-benzoesaeure；4-(Pentan-3-yl)benzoic acid；4-pentan-3-ylbenzoic acid
• CAS: 860698-63-1
• 化学式: C₁₂H₁₆O₂
• 分子量: 192.258
• InChiKey: WCTRNKQBQXROAT-UHFFFAOYSA-N

物化性质

• 熔点：
  104-105 °C
• 沸点：
  303.8±21.0 °C(Predicted)
• 密度：
  1.038±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(1-ethylpropyl)benzoic acid 在 氯化亚砜 、 一水合肼 、 溶剂黄146 、 N,N-二甲基甲酰胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 4-(1-ethylpropyl)benzoic acid [3-(1-ethylpropyl)-2-hydroxy-benzylidene]-hydrazide
  参考文献：
  名称：

  Engineered Chimeric Enzymes as Tools for Drug Discovery:  Generating Reliable Bacterial Screens for the Detection, Discovery, and Assessment of Estrogen Receptor Modulators

  摘要：

  Engineered protein-based sensors of ligand binding have emerged as attractive tools for the discovery of therapeutic compounds through simple screening systems. We have previously shown that engineered chimeric enzymes, which combine the ligand-binding domains of nuclear hormone receptors with a highly sensitive thymidylate synthase reporter, yield simple sensors that report the presence of hormone-like compounds through changes in bacterial growth. This work describes an optimized estrogen sensor in Escherichia coli with extraordinary reliability in identifying diverse estrogenic compounds and in differentiating between their agonistic/antagonistic pharmacological effects. The ability of this system to assist the discovery of new estrogen-mimicking compounds was validated by screening a small compound library, which led to the identification of two structurally novel estrogen receptor modulators and the accurate prediction of their agonistic/antagonistic biocharacter in human cells. Strong evidence is presented here that the ability of our sensor to detect ligand binding and recognize pharmacologically critical properties arises from allosteric communication between the artificially combined protein domains, where different ligand-induced conformational changes in the receptor are transmitted to the catalytic domain and translated to distinct levels of enzymic efficiency. To the best of our knowledge, this is one of the first examples of an engineered enzyme with the ability to sense multiple receptor conformations and to be either activated or inactivated depending on the nature of the bound effector molecule. Because the proposed mechanism of ligand dependence is not specific to nuclear hormone receptors, we anticipate that our protein engineering strategy will be applicable to the construction of simple sensors for different classes of (therapeutic) binding proteins.

  DOI：

  10.1021/ja067754j
• 作为产物：
  描述：

  3-苯基戊烷 在 正丁基锂 、 溴 作用下， 以 乙醚 为溶剂， 反应 17.0h， 生成 4-(1-ethylpropyl)benzoic acid
  参考文献：
  名称：

  Engineered Chimeric Enzymes as Tools for Drug Discovery:  Generating Reliable Bacterial Screens for the Detection, Discovery, and Assessment of Estrogen Receptor Modulators

  摘要：

  Engineered protein-based sensors of ligand binding have emerged as attractive tools for the discovery of therapeutic compounds through simple screening systems. We have previously shown that engineered chimeric enzymes, which combine the ligand-binding domains of nuclear hormone receptors with a highly sensitive thymidylate synthase reporter, yield simple sensors that report the presence of hormone-like compounds through changes in bacterial growth. This work describes an optimized estrogen sensor in Escherichia coli with extraordinary reliability in identifying diverse estrogenic compounds and in differentiating between their agonistic/antagonistic pharmacological effects. The ability of this system to assist the discovery of new estrogen-mimicking compounds was validated by screening a small compound library, which led to the identification of two structurally novel estrogen receptor modulators and the accurate prediction of their agonistic/antagonistic biocharacter in human cells. Strong evidence is presented here that the ability of our sensor to detect ligand binding and recognize pharmacologically critical properties arises from allosteric communication between the artificially combined protein domains, where different ligand-induced conformational changes in the receptor are transmitted to the catalytic domain and translated to distinct levels of enzymic efficiency. To the best of our knowledge, this is one of the first examples of an engineered enzyme with the ability to sense multiple receptor conformations and to be either activated or inactivated depending on the nature of the bound effector molecule. Because the proposed mechanism of ligand dependence is not specific to nuclear hormone receptors, we anticipate that our protein engineering strategy will be applicable to the construction of simple sensors for different classes of (therapeutic) binding proteins.

  DOI：

  10.1021/ja067754j
• 作为试剂：
  描述：

  1-羟基哌啶 在 4-(1-ethylpropyl)benzoic acid 、 N,N'-羰基二咪唑 作用下， 以 二氯甲烷 为溶剂， 生成 piperidin-1-yl 4-(diethylamino)benzoate
  参考文献：
  名称：

  未活化烯烃和炔烃的区域选择性和对映选择性铜催化氢氨基羰基化

  摘要：

  我们在此报告了一种在温和条件下对未活化烯烃进行区域选择性和对映选择性铜催化的反马尔可夫尼科夫氢氨基羰基化的通用方法。该反应可耐受多种官能团，适用于不同类别的烯烃。在该催化系统下，炔烃也可与级联氢化-加氢氨基羰基化过程兼容生成烷基酰胺。

  DOI：

  10.1002/anie.202309993

文献信息

• Inhibitors of Transthyretin Amyloid Fibril Formation
  申请人：Kelly Jeffery W.

  公开号：US20090054629A1

  公开（公告）日：2009-02-26

  Bisaryloxime ethers and bisarylhydroazones are shown to be effective for inhibiting formation of amyloid fibrils of transthyretin.

  Bisaryloxime醚和bisarylhydroazones已被证明对抑制转甲状腺原蛋白淀粉样纤维的形成具有有效性。
• BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS
  申请人：Rottapharm Biotech S.r.l.

  公开号：EP3725777A1

  公开（公告）日：2020-10-21

  The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.

  本发明涉及新的式（I）化合物、含有它们的药物组合物，以及它们在癌症（最好是胶质母细胞瘤）药物治疗中的用途。
• Spirocyclic compounds as tryptophan hydroxylase inhibitors
  申请人：Roivant Sciences GmbH

  公开号：US10350208B2

  公开（公告）日：2019-07-16

  The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及的螺环化合物是色氨酸羟化酶（TPH），特别是同工酶 1（TPH1）的抑制剂，可用于治疗与外周血清素相关的疾病或失调，例如包括胃肠道、心血管、肺、炎症、代谢和低骨量疾病，以及血清素综合征和癌症。
• Studies in Stereochemistry. VIII. Molecular Rearrangements During Lithium Aluminum Hydride Reductions in the 3-Phenyl-2-pentanol and 2-Phenyl-3-pentanol Systems¹
  作者：Donald J. Cram

  DOI：10.1021/ja01129a004

  日期：1952.5
• Friedel—Crafts Acylations of Some Sterically Hindered Alkylbenzenes
  作者：G. F. Hennion、S. F. deC. McLeese

  DOI：10.1021/ja01262a055

  日期：1942.10